Journal ArticleDOI
ERBB receptors and cancer: the complexity of targeted inhibitors.
Nancy E. Hynes,Heidi Lane +1 more
TLDR
This work discusses the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response, and many ERBB inhibitors used in the clinic.Abstract:
ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.read more
Citations
More filters
Journal ArticleDOI
Cancer Genome Landscapes
Bert Vogelstein,Nickolas Papadopoulos,Victor E. Velculescu,Shibin Zhou,Luis A. Diaz,Kenneth W. Kinzler +5 more
TL;DR: This work has revealed the genomic landscapes of common forms of human cancer, which consists of a small number of “mountains” (genes altered in a high percentage of tumors) and a much larger number of "hills" (Genes altered infrequently).
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
TL;DR: In addition to their role in extracellular matrix turnover and cancer cell migration, MMPs regulate signaling pathways that control cell growth, inflammation, or angiogenesis and may even work in a nonproteolytic manner.
Journal ArticleDOI
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve,Richard M. Neve,Koei Chin,Jane Fridlyand,Jennifer Yeh,Frederick L. Baehner,Tea Fevr,Laura Clark,Nora Bayani,Jean-Philippe Coppe,Frances Tong,Terence P. Speed,Paul T. Spellman,Sandy DeVries,Anna Lapuk,Nicholas J. Wang,Wen-Lin Kuo,Jackie L. Stilwell,Daniel Pinkel,Donna G. Albertson,F. M. Waldman,Frank McCormick,Robert B. Dickson,Michael D. Johnson,Marc E. Lippman,Stephen P. Ethier,Adi F. Gazdar,Joe W. Gray,Joe W. Gray +28 more
TL;DR: It is shown, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations.
Journal ArticleDOI
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado,Michael S. Wolf,Marc Peeters,Eric Van Cutsem,Salvatore Siena,Daniel J. Freeman,Todd Juan,Robert Sikorski,Sid Suggs,Robert Radinsky,Scott D. Patterson,David D. Chang +11 more
TL;DR: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy.
References
More filters
Journal ArticleDOI
Akt kinases in breast cancer and the results of adjuvant therapy
Olle Stål,Gizeh Pérez-Tenorio,Linda Åkerberg,Birgit Olsson,Bo Nordenskjöld,Lambert Skoog,Lars Erik Rutqvist +6 more
TL;DR: Activation of the Akt pathway is correlated with erbB2 overexpression in breast cancer and the results suggest that Akt may predict the local control benefit from radiotherapy.
Journal ArticleDOI
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
TL;DR: In this article, structural studies have provided important insights into why these very different kinases share similar oncogenic hot spots and why the platelet-derived growth factor receptor (PDGFR) juxtamembrane region is also a frequent target.
Journal ArticleDOI
Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy
Gong Wu,Rolf F. Barth,Weilian Yang,Madhumita Chatterjee,Werner Tjarks,Michael J. Ciesielski,Robert A. Fenstermaker +6 more
TL;DR: The purpose of the present study was to investigate the use of the chimeric MoAb cetuximab (IMC-C225), which is directed against EGFR and EGFRvIII, as a boron delivery agent for neutron capture therapy (NCT) of brain tumors.
Journal ArticleDOI
Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
TL;DR: The epidermal growth factor (EGF) receptor and its ligands are overexpressed in human pancreatic carcinoma and may contribute to the pathophysiology of these tumors.
Journal ArticleDOI
Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta.
TL;DR: E2 induces a slow but persistent activation of Erk in MCF-7 breast carcinoma cells and evaluation of downstream signaling revealed that E2-induced Erk activation is mediated by a HRG/HER-2/PKC-δ/Ras pathway that could be crucial for E1-dependent growth-promoting effects in early stages of tumor progression.
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more